Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EPS watch

EPS watch

EPS watch
Actelion (SWX:ATLN) was the big loser last week, down 15% - about $1.1 billion in market cap - after reporting that 3Q07 sales of Tracleer for pulmonary arterial hypertension (PAH) fell 4% to CHF286.6 million ($245.5 million) from the prior quarter. ATLN cited the effects of a weakened dollar and noted a large distributor placed an order a few days after the end of the third quarter. The company also acknowledged competition in PAH from Letairis ambrisentan, which was launched by Gilead (GILD) in June. Genentech (DNA) also shed about $2.4 billion in valuation as analysts believe the bellwether's earnings were "in-line" and "uninspiring." In its conference call, DNA said revenue and earnings growth rates are likely to come

Read the full 1239 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers